PortfoliosLab logoPortfoliosLab logo
ILKAY vs. AZN
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ILKAY vs. AZN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Iluka Resources Ltd ADR (ILKAY) and AstraZeneca PLC (AZN). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ILKAY achieves a 52.99% return, which is significantly higher than AZN's -2.12% return. Over the past 10 years, ILKAY has underperformed AZN with an annualized return of 11.57%, while AZN has yielded a comparatively higher 14.81% annualized return.


ILKAY

1D
-3.21%
1M
-0.85%
YTD
52.99%
6M
28.50%
1Y
142.51%
3Y*
-7.82%
5Y*
0.20%
10Y*
11.57%

AZN

1D
-0.66%
1M
-3.91%
YTD
-2.12%
6M
-0.95%
1Y
26.16%
3Y*
9.19%
5Y*
11.73%
10Y*
14.81%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ILKAY vs. AZN - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ILKAY
Iluka Resources Ltd ADR
52.99%19.25%-26.93%-30.67%-8.72%83.16%24.66%6.24%-17.73%44.05%
AZN
AstraZeneca PLC
-2.12%43.30%-0.62%1.44%19.14%19.66%3.12%35.68%13.86%33.10%

Correlation

The correlation between ILKAY and AZN is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.08

Correlation (3Y)
Calculated over the trailing 3-year period

0.04

Correlation (5Y)
Calculated over the trailing 5-year period

0.06

Correlation (10Y)
Calculated over the trailing 10-year period

0.03

Correlation (All Time)
Calculated using the full available price history since Feb 7, 2011

0.04

Fundamentals

Market Cap

ILKAY:

$2.43B

AZN:

$275.17B

EPS

ILKAY:

-$1.11

AZN:

$6.66

PS Ratio

ILKAY:

1.29

AZN:

4.55

PB Ratio

ILKAY:

1.18

AZN:

5.81

Total Revenue (TTM)

ILKAY:

$1.89B

AZN:

$60.44B

Gross Profit (TTM)

ILKAY:

$789.87M

AZN:

$49.37B

EBITDA (TTM)

ILKAY:

$565.16M

AZN:

$20.47B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ILKAY vs. AZN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ILKAY
ILKAY Risk / Return Rank: 8383
Overall Rank
ILKAY Sharpe Ratio Rank: 8787
Sharpe Ratio Rank
ILKAY Sortino Ratio Rank: 8282
Sortino Ratio Rank
ILKAY Omega Ratio Rank: 8282
Omega Ratio Rank
ILKAY Calmar Ratio Rank: 8484
Calmar Ratio Rank
ILKAY Martin Ratio Rank: 7979
Martin Ratio Rank

AZN
AZN Risk / Return Rank: 7070
Overall Rank
AZN Sharpe Ratio Rank: 7272
Sharpe Ratio Rank
AZN Sortino Ratio Rank: 7070
Sortino Ratio Rank
AZN Omega Ratio Rank: 6565
Omega Ratio Rank
AZN Calmar Ratio Rank: 7171
Calmar Ratio Rank
AZN Martin Ratio Rank: 7474
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ILKAY vs. AZN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Iluka Resources Ltd ADR (ILKAY) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ILKAYAZNDifference

Sharpe ratio

Return per unit of total volatility

1.89

1.05

+0.84

Sortino ratio

Return per unit of downside risk

2.43

1.75

+0.68

Omega ratio

Gain probability vs. loss probability

1.33

1.20

+0.12

Calmar ratio

Return relative to maximum drawdown

3.26

1.71

+1.55

Martin ratio

Return relative to average drawdown

6.29

4.70

+1.59

ILKAY vs. AZN - Sharpe Ratio Comparison

The current ILKAY Sharpe Ratio is 1.89, which is higher than the AZN Sharpe Ratio of 1.05. The chart below compares the historical Sharpe Ratios of ILKAY and AZN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


ILKAYAZNDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.89

1.05

+0.84

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.00

0.49

-0.49

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.23

0.60

-0.37

Sharpe Ratio (All Time)

Calculated using the full available price history

0.07

0.49

-0.42

Drawdowns

ILKAY vs. AZN - Drawdown Comparison

The maximum ILKAY drawdown since its inception was -79.51%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for ILKAY and AZN.


Loading charts...

Drawdown Indicators


ILKAYAZNDifference

Max Drawdown

Largest peak-to-trough decline

-79.51%

-48.94%

-30.57%

Max Drawdown (1Y)

Largest decline over 1 year

-43.96%

-15.43%

-28.53%

Max Drawdown (3Y)

Largest decline over 3 years

-76.29%

-27.87%

-48.42%

Max Drawdown (5Y)

Largest decline over 5 years

-77.94%

-27.87%

-50.07%

Max Drawdown (10Y)

Largest decline over 10 years

-77.94%

-27.87%

-50.07%

Current Drawdown

Current decline from peak

-30.66%

-15.43%

-15.23%

Average Drawdown

Average peak-to-trough decline

-47.27%

-11.37%

-35.90%

Ulcer Index

Depth and duration of drawdowns from previous peaks

22.74%

5.60%

+17.14%

Volatility

ILKAY vs. AZN - Volatility Comparison

Iluka Resources Ltd ADR (ILKAY) has a higher volatility of 16.25% compared to AstraZeneca PLC (AZN) at 6.36%. This indicates that ILKAY's price experiences larger fluctuations and is considered to be riskier than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ILKAYAZNDifference

Volatility (1M)

Calculated over the trailing 1-month period

16.25%

6.36%

+9.89%

Volatility (6M)

Calculated over the trailing 6-month period

46.51%

17.06%

+29.45%

Volatility (1Y)

Calculated over the trailing 1-year period

76.31%

25.18%

+51.13%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

54.59%

23.94%

+30.65%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

51.17%

24.90%

+26.27%

Dividends

ILKAY vs. AZN - Dividend Comparison

ILKAY's dividend yield for the trailing twelve months is around 0.60%, less than AZN's 3.02% yield.


PositionTTM20252024202320222021202020192018201720162015
AZN
AstraZeneca PLC
3.02%1.70%2.27%2.15%2.12%2.35%2.80%2.81%3.69%3.95%5.01%4.06%
ILKAY
Iluka Resources Ltd ADR
0.60%1.03%1.68%3.58%7.39%1.33%73.30%2.45%4.10%0.55%9.11%2.95%

Financials

ILKAY vs. AZN - Financials Comparison

This section allows you to compare key financial metrics between Iluka Resources Ltd ADR and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B202120222023202420252026
429.57M
15.29B
(ILKAY) Total Revenue
(AZN) Total Revenue
Values in USD except per share items

ILKAY vs. AZN - Profitability Comparison

The chart below illustrates the profitability comparison between Iluka Resources Ltd ADR and AstraZeneca PLC over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-20.0%0.0%20.0%40.0%60.0%80.0%100.0%202120222023202420252026
-29.0%
82.5%
Portfolio components
ILKAY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Iluka Resources Ltd ADR reported a gross profit of -124.38M and revenue of 429.57M. Therefore, the gross margin over that period was -29.0%.

AZN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a gross profit of 12.61B and revenue of 15.29B. Therefore, the gross margin over that period was 82.5%.

ILKAY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Iluka Resources Ltd ADR reported an operating income of -205.17M and revenue of 429.57M, resulting in an operating margin of -47.8%.

AZN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported an operating income of 4.25B and revenue of 15.29B, resulting in an operating margin of 27.8%.

ILKAY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Iluka Resources Ltd ADR reported a net income of -373.42M and revenue of 429.57M, resulting in a net margin of -86.9%.

AZN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a net income of 3.08B and revenue of 15.29B, resulting in a net margin of 20.2%.


Frequently Asked Questions


ILKAY and AZN have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ILKAY has higher volatility (16.25%) compared to AZN (6.36%). In terms of maximum drawdown, ILKAY dropped -79.51% vs AZN's -48.94%.

ILKAY currently has the higher Sharpe Ratio (1.89 vs 1.05), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ILKAY and AZN

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer